Investment Analysts’ Weekly Ratings Changes for Maze Therapeutics (MAZE)

Several analysts have recently updated their ratings and price targets for Maze Therapeutics (NASDAQ: MAZE):

• 9/24/2026 – Maze Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $110.00 price target on the stock.
• 9/23/2026 – Maze Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/23/2026 – Maze Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating and a $50.00 price target on the stock.
• 9/23/2026 – Maze Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $48.00 price target on the stock.
• 9/22/2026 – Maze Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.
• 9/21/2026 – Maze Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/24/2026 – Maze Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/15/2026 – Maze Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/12/2026 – Maze Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.

Insider Buying and Selling

In other Maze Therapeutics news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the completion of the sale, the chief executive officer directly owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the transaction, the insider directly owned 26,250 shares of the company’s stock, valued at $723,975. This trade represents a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 134,849 shares of company stock worth $3,582,240 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Get Maze Therapeutics Inc alerts:

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.

Featured Stories

• Five stocks we like better than Maze Therapeutics
• L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
• Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
• Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
• O’Reilly Automotive’s Stock Slump Hides a Stronger Business

Receive News & Ratings for Maze Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.